Your Good Partner in Biology Research

Human insulin-like growth factors binding protein 2,IGFBP-2 ELISA Kit

  • 中文名称:
    人胰岛素样生长因子结合蛋白2(IGFBP2)酶联免疫试剂盒
  • 货号:
    CSB-E04588h
  • 规格:
    96T/48T
  • 价格:
    ¥3200/¥2500
  • 其他:

产品详情

  • 产品描述:
        IGFBP2 (Insulin-like growth factor-binding protein 2)是一种蛋白质,主要作用是与IGF(胰岛素样生长因子)结合,调控细胞生长和代谢。IGFBP2的高表达与许多癌症相关,例如卵巢癌、结直肠癌和肺癌等。此外,IGFBP2在神经发育和神经退行性疾病中也起着重要作用。生物学含义上,IGFBP2可作为肿瘤标志物用于临床诊断和治疗。在正常体内,IGFBP2含量较低,但在癌症患者中常常高表达。
        j9九游会登录入口首页生物所提供的Human insulin-like growth factors binding protein 2,IGFBP-2 ELISA Kit属于ELISA检测试剂盒,采用双抗夹心法定量检测人血清、血浆、组织匀浆样本中的IGFBP2,其灵敏度为0.195 ng/mL,检测范围为0.78 ng/mL-50 ng/mL。
     
  • 别名:
    BP 2 ELISA Kit; BP2 ELISA Kit; IBP 2 ELISA Kit; IBP-2 ELISA Kit; IBP2 ELISA Kit; IBP2_HUMAN ELISA Kit; IGF binding protein 2 ELISA Kit; IGF BP53 ELISA Kit; IGF-binding protein 2 ELISA Kit; IGFBP 2 ELISA Kit; IGFBP-2 ELISA Kit; IGFBP2 ELISA Kit; IGFBP53 ELISA Kit; Insulin like growth factor binding protein 2 36kDa ELISA Kit; Insulin like growth factor binding protein 2 ELISA Kit; Insulin like growth factor-binding protein 2 precursor ELISA Kit; Insulin-like growth factor-binding protein 2 ELISA Kit
  • 缩写:
    IGFBP2
  • Uniprot No.:
  • 种属:
    Homo sapiens (Human)
  • 样本类型:
    serum, plasma, tissue homogenates
  • 检测范围:
    0.78 ng/mL-50 ng/mL
  • 灵敏度:
    0.195 ng/mL
  • 反应时间:
    1-5h
  • 样本体积:
    50-100ul
  • 检测波长:
    450 nm
  • 研究领域:
    Signal Transduction
  • 测定原理:
    quantitative
  • 测定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 线性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human IGFBP-2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
      Sample Serum(n=4)  
    1:5 Average % 97  
    Range % 91-105  
    1:10 Average % 95  
    Range % 92-98  
    1:20 Average % 92  
    Range % 86-99  
    1:40 Average % 94  
    Range % 89-100  
  • 回收率:
    The recovery of human IGFBP-2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 96 89-101  
    EDTA plasma (n=4) 94 88-99  
                 
                 
  • 标准曲线:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    50 2.935 2.952 2.944 2.767  
    25 2.026 2.076 2.051 1.874  
    12.5 1.088 1.046 1.067 0.890  
    6.25 0.592 0.583 0.588 0.411  
    3.12 0.361 0.337 0.349 0.172  
    1.56 0.278 0.259 0.269 0.092  
    0.78 0.232 0.229 0.231 0.054  
    0 0.176 0.177 0.177    
  • 数据处理:
  • 货期:
    3-5 working days

产品评价

靶点详情

  • 最新研究进展:
    胰岛素样生长因子结合蛋白2(IGFBP2)是IGF系统中的重要组成部分。IGFBP2具有促进细胞增殖、生存和肿瘤形成的作用。最近的研究发现,IGFBP2在多种肿瘤中表达升高,如前列腺癌、肺癌、乳腺癌等。此外,IGFBP2还被发现与肿瘤的浸润、转移和预后相关。
  • 功能:
    Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
  • 基因功能参考文献:
    1. Following IGFBP2 knockdown using rAAV2-ZsGreen-shRNA-hIGFBP2, matrix metalloproteinase2 expression was significantly reduced in tumor tissues compared with that in rAAV2ZsGreenshRNAscramble treated tumor tissues. PMID: 29344663
    2. IGFBP2 overexpression increased the expression of p-p65 and nuclear p65, while IGFBP2 knockdown reduced the expression of p-p65 and nuclear p65. PMID: 29228449
    3. The associated effects appear to be mediated by inhibition of IGFBP-2 expression and stimulation of p21 expression. This suggests that simulated microgravity might represent a promising method to discover new targets for glioma therapeutic strategy. PMID: 28707224
    4. these results suggest that IGFBP2 plays an important role in promoting tumorigenesis, through estrogen and ERalpha signaling pathway. PMID: 28410230
    5. patients with low IGFBP2 expressiondisplay a clear advantage in overall and disease-free survival, whereas those with high IGFBP2 expressionhave worse median survival than IDH-wildtype patients. PMID: 27852048
    6. The interaction of IGFBP2 and p63 might account for the pathogenesis of rhabdomyosarcoma tumors. PMID: 28129571
    7. Co-ordinated and reciprocal alteration in IGFBP-2 and -5 expression may play a role in the acquisition of endocrine resistance in breast cancer. PMID: 27050076
    8. We verified that NFIA binds to the IGFBP2 promoter and transcriptionally enhances IGFBP2 expression levels. We identified that NFIA-mediated IGFBP2 signaling pathways are involved in miR-302b-induced glioma cell death. PMID: 28323865
    9. Insulin-like growth factor binding protein 2 potentiates glioblastoma tumor growth by the activation of the beta-catenin pathway through its C-terminal domain, and their coexpression possibly contributes to worse patient prognosis. PMID: 27044294
    10. mechanistic investigations defined insulin-like growth factor binding protein 2 (IGFBP2)as a direct and functional downstream target of microRNA-592, which was involved in the microRNA-592-mediated tumor-suppressive effects in glioma cells. PMID: 28718372
    11. IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of invasive ductal adenocarcinoma of pancreas patients. PMID: 27579675
    12. In human whole blood cells, methylation of IGFBP2 at the homologous CpG site was increased in obese men with impaired glucose tolerance. In conclusion, our data show that increased methylation of hepatic Igfbp2 during infancy predicts the development of fatty liver later in life and is linked to deterioration of glucose metabolism. PMID: 27126637
    13. Data suggest that circulating insulin-like growth factor-binding protein 2 (IGFBP2) has potential as a biomarker predicting prognosis for gastric cancer patients. PMID: 28036255
    14. Together, this study validated that T-2 toxin exposure might promote the progression of KBD by inducing chondrocyte injury, suppressing matrix synthesis and accelerating cellular catabolism through IGFBP2. Therefore, this research will elucidate a new insight about how T-2 toxin participate in the pathogenesis of KBD. PMID: 27416762
    15. IGFBP2 protein levels are altered in type 2 diabetes mellitus patients and associated with cardiovascular disease risk factors. PMID: 28179448
    16. The monoclonal gammopathy of undetermined significance and multiple myeloma patients displayed a significant increase in intact IGFBP-2 and decrease in intact IGFBP-3 in the circulation compared to control individuals. PMID: 27111220
    17. In patients with malignant and borderline ovarian tumors, the level of IGFBP-2 was higher than in healthy women and in patients with benign ovarian tumors. PMID: 27165066
    18. IGFBP2 and SOCS3 were up-regulated in Kashin-Beck disease chondrocytes and decreased with increasing selenium concentrations. IGFBP2 expressed highest in the middle zone of KBD cartilage, SOCS3 expressed higher in the middle and deep zone. IGFBP2 and SOCS3 may be the biomarkers for KBD diagnosis and evaluating the effect of selenium supplement. PMID: 27099071
    19. There was a positive correlation between the IGFBP2 levels of and those of inflammatory mediators in HIV Infections. PMID: 25890304
    20. IGFBP-2 overexpression in HUVECs promoted endothelial progenitor cells(EPC)-endothelial adhesion. The RGD motif in its C-domain is required for interaction with integrin alpha5beta1. PMID: 26076738
    21. Serum IGFBP2 reflects disease activity and renal pathology changes in lupus nephritis. PMID: 26616478
    22. Data show that modulation of insulin like growth factor binding protein 2 (IGFBP2) expression affects proliferation, motility, and chemosensitization of eophageal adenocarcinoma (EAC) cells in a serum-dependent manner. PMID: 26317790
    23. Identification of a novel tumor-promoting function for IGFBP2 of activating EGFR/STAT3 signaling and facilitating EGFR accumulation in the nucleus, thereby deregulating EGFR signaling by two distinct mechanisms. PMID: 25893308
    24. that age-specific cognitive decline may be moderated by IGF-BP2 PMID: 26043140
    25. Serum IGFBP2 was increased in patients with hepatocellular carcinoma compared to healthy controls, but lower than in patients with liver cirrhosis. PMID: 26068014
    26. The expression levels of maspin were lower in the cisplatin-resistant tissue and cells, and was enhanced by IGFBP-2 inhibition. PMID: 26080829
    27. Insulin-like growth factor binding protein 2 is strongly associated with restoration of keratocyte phenotype in HCFs. PMID: 26559475
    28. Elevated serum IGFBP2 levels might play a role in the postnatal growth retardation phenotype of Pallister-Killian syndrome. PMID: 25900123
    29. IGFBP-2 secreted by mature adipocytes plays a key role in promoting the metastatic ability of MCF-7 breast cancer cells PMID: 25747684
    30. These results implicate TRIB3 and IGFBP2, both of which are known to be overexpressed in several types of cancers, as pro-survival modulators of cell viability in nutrient-deficient microenvironments. PMID: 26094770
    31. IGFBP-2 may have a role in metabolic syndrome and is independently associated with VLDL triglycerides PMID: 25463100
    32. Report changes in serum levels of protein molecular forms of insulin-like growth factor binding protein-2 with age. PMID: 25106097
    33. Low IGFBP2 expression is associated with adrenocortical carcinoma. PMID: 24833102
    34. Elevated plasma IGFBP-2 levels after combined postoperative radiotherapy and chemotherapy in elderly glioblastoma patients correlate with poor Karnofsky performance status score and predicts poor prognosis. PMID: 24690948
    35. The amount of IGFBP-2 monomer increased in sera from all studied patients compared to controls, whereas the amount of IGFBP-2/alpha2M complexes most often decreased, being significantly reduced in patients with pancreas, colon, breast or ovary tumor. PMID: 25746666
    36. A combined profile of preoperative IGFBP-2, GFAP, and YKL-40 plasma levels could serve as an additional diagnostic tool for patients with inoperable brain lesions suggestive of Glioblastoma multiforme. PMID: 25139333
    37. Constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo. PMID: 24292683
    38. Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel for pancreatic cancer. PMID: 24308545
    39. two IGFBP2 heparin-binding domains contribute differentially to 2- or 3-carbon O-sulfated glycosaminoglycans binding in free IGFBP2 and the IGF2/IGFBP2 protein complex. PMID: 24604839
    40. Increased serum concentration significantly and independently associated with long-term cardiovascular disease mortality in patients with lower-extremity peripheral artery disease PMID: 24548188
    41. Exogenous IGFBP-2 induces proliferation, invasion, and chemoresistance in glioma cells via integrin-beta1/ERK signaling. PMID: 25093489
    42. IGFBP2 is a critical cell-autonomous factor that promotes the survival and migration of acute leukemia cells. PMID: 24191913
    43. insulin-like growth factors bound to IGFBP-3 remain in the circulation, whereas those bound to IGFBP-2 freely reach target tissues. PMID: 24051179
    44. High IGFBP-2 gene expression is asssociated with cytomegalovirus positive glioblastoma multiforme. PMID: 24352760
    45. the IGFBP2/FAK pathway is causally associated with dasatinib resistance. PMID: 24130049
    46. IGFBP2 overexpression is associated with metastasis and poor survival in NSCLC patients. PMID: 24682597
    47. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PMID: 24069370
    48. IGFBP-2 in complex with alpha2 macroglobulin was 2.5 times lower in cancer patients. PMID: 24275430
    49. IGFBP-2 possesses a functional nuclear localization signal sequence and IGFBP-2 actively translocates into the nucleus by a classical nuclear import mechanism, involving formation of IGFBP-2 complexes with importin-alpha. PMID: 23435424
    50. Increased glucose concentrations inhibited the efficacy of docetaxel at inducing apoptosis, which was associated with increased IGFBP2 production as a result of glucose-induced acetylation of histones bound to the IGFBP2 promoter. PMID: 23959956

    显示更多

    收起更多

  • 亚细胞定位:
    Secreted.
  • 数据库链接:

    HGNC: 5471

    OMIM: 146731

    KEGG: hsa:3485

    STRING: 9606.ENSP00000233809

    UniGene: Hs.438102